openPR Logo
Press release

Aspergillosis Therapeutics Surge with New Azoles & Rising Immunocompromised Cases in Japan | Pfizer, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals

08-12-2025 10:45 PM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Aspergillosis Market

Aspergillosis Market

Global Aspergillosis Market reached US$ 3.2 billion in 2022 and is expected to reach US$ 6.5 billion by 2030, growing with a CAGR of 5.6% during the forecast period 2024-2031.

Aspergillosis Market Report by DataM Intelligence offers a detailed assessment of the global respiratory and mycology diagnostics landscape, highlighting market size, key players, and critical growth drivers. With rising demand for rapid molecular diagnostics, new antifungal agents, and expanded stewardship programs, the report delivers strategic insights for stakeholders from 2025 to 2033.

In 2025, Japan reported discoveries of hybrid Aspergillus strains with antifungal resistance that underscore the need for improved molecular identification tools, while commercial uptake of isavuconazole (Cresemba) in Japan delivered early sales momentum for broad-spectrum azoles, reinforcing the region's expanding antifungal market.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/aspergillosis-market?ophp

Aspergillosis Market Competitors Overview:

Pfizer, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals, Eugia Pharma, krishlar Pharmaceuticals, Merck, Aozeal, Hikma, Xellia Pharmaceuticals and among others.

Important Industry Updates:

In June 2023, Endo International plc announced that its Par Sterile Products business has begun shipping posaconazole injection (18 mg/mL), the first generic version of Merck's Noxafil in the U.S., following final approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application. Posaconazole injection is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections.

In February 2023, Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE technology, announced the first patient dosed in a Phase 2b trial evaluating the safety and efficacy of PUR1900 in subjects with Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. PUR1900 is the company's iSPERSE-enabled dry powder formulation of itraconazole, developed for inhaled pulmonary delivery.

Methodology and Scope

The Aspergillosis Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/aspergillosis-market?ophp

Aspergillosis Market Segments Overview:

∎ By Type

Chronic Pulmonary Aspergillosis
Allergic Bronchopulmonary Aspergillosis (ABPA)
Invasive Aspergillosis
Invasive Fungal Rhinosinusitis
Invasive Pulmonary Aspergillosis

∎ By Drug Type

Isavuconazole
Voriconazole
Amphotericin-B
Itraconazole
Corticosteroids
Posaconazole
Others

∎ By Route of Administration

Oral
Intravenous

∎ By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Overview for Aspergillosis Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=aspergillosis-market

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Aspergillosis market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Aspergillosis market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Aspergillosis Therapeutics Surge with New Azoles & Rising Immunocompromised Cases in Japan | Pfizer, Therma Fisher Scientific, Rewine Pharmaceuticals, Teva Pharmaceuticals here

News-ID: 4142688 • Views:

More Releases from DataM intelligence 4 Market Research LLP

Intelligent Emergency Response Systems and Infrastructure Market Rises as AI Dispatch, Sensor Networks and Resilient Cities Converge
Intelligent Emergency Response Systems and Infrastructure Market Rises as AI Dis …
The global Intelligent Emergency Response Systems and Infrastructure (IRSI) market was valued at US$ 1.3 billion in 2022 and is projected to reach US$ 2.1 billion by 2031, growing at a CAGR of 6.1% during the forecast period from 2024 to 2031. Market growth is driven by increasing investments in smart public safety infrastructure, AI-powered emergency response systems, and the rising need for disaster preparedness and real-time incident management.The Intelligent
Anti-Senescence Therapeutics Market Moves From Longevity Hype Toward Biomarker-Led Drug Development for Age-Related Disease
Anti-Senescence Therapeutics Market Moves From Longevity Hype Toward Biomarker-L …
The global anti-senescence therapeutics market was valued at USD 33.03 billion in 2025 and is projected to reach USD 53.39 billion by 2033, growing at a CAGR of 6.7% during the forecast period from 2026 to 2033. Market growth is driven by increasing investments in longevity research, rising prevalence of age-related diseases, and advancements in regenerative medicine and senolytic therapies. The Anti-Senescence Therapeutics Market is entering a new phase of
Molecular Biosensors Market Accelerates as Point-of-Care Testing Moves Toward Faster, Connected and More Targeted Detection
Molecular Biosensors Market Accelerates as Point-of-Care Testing Moves Toward Fa …
The global Molecular Biosensors Market was valued at USD 30.80 billion in 2024, increased to USD 33.55 billion in 2025, and is estimated to reach USD 36.55 billion in 2026. The market is projected to grow to USD 56.04 billion by 2031, registering a CAGR of 8.93% during the forecast period from 2026 to 2031. These advanced sensing technologies combine molecular recognition with highly sensitive detection systems, enabling clinicians to
ECG Patches and Holter Monitor Market Expands as Remote Cardiac Monitoring Shifts Arrhythmia Detection Beyond the Clinic
ECG Patches and Holter Monitor Market Expands as Remote Cardiac Monitoring Shift …
The Global ECG Patches and Holter Monitor Market reached US$ 1,864.54 million in 2024 and is projected to grow to US$ 5,950.62 million by 2033, expanding at a CAGR of 13.7% during the forecast period (2025-2033). This robust growth reflects the increasing shift from short-term, wearable monitoring solutions that enable earlier detection of arrhythmias and other heart rhythm disorders. Advances in wearable ECG patches, cloud-connected monitoring platforms, and AI-assisted

All 5 Releases


More Releases for Aspergillosis

Aspergillosis Pipeline: 20+ Promising Therapies Poised to Redefine the Aspergill …
The treatment paradigm for Aspergillosis, a serious fungal infection primarily affecting immunocompromised individuals, is rapidly evolving with a robust pipeline of antifungal agents under clinical and preclinical development. Leading pharmaceutical and biotech companies such as Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, and TFF Pharmaceuticals are at the forefront, developing next-generation therapies aimed at overcoming resistance issues and improving patient outcomes through novel mechanisms of action and targeted
Leading Growth Driver in the Aspergillosis Treatment Market in 2025: Rising Prev …
What market dynamics are playing a key role in accelerating the growth of the aspergillosis treatment market? The escalating instances of fungal infections are anticipated to thrust the expansion of the aspergillosis treatment market. Mycosis, another name for fungal infections, can trigger infections in both humans and animals. Aspergillosis, a type of fungal infection, can affect an array of body parts such as the respiratory system, lungs, brain, kidneys, and other
Leading Growth Driver in the Aspergillosis Treatment Market in 2025: Rising Prev …
"What Are the Market Size and Growth Forecast for the Aspergillosis Treatment Market? The aspergillosis treatment market has shown strong growth in recent years. It is expected to grow from $3.14 billion in 2024 to $3.33 billion in 2025, at a CAGR of 5.8%. The past expansion can be attributed to advancements in diagnostics, rising demand for antifungal medications, increased disease incidence, and the growing number of invasive medical procedures. The aspergillosis
Aspergillosis Treatment Market Size & Share Report, 2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Aspergillosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $3.98 billion In 2028 At
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Increasing prevalence of Aspergillosis and favorable government regulations are …
Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to Aspergillus induced infection. Common Aspergillus infections include invasive Aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma (CPA). Invasive aspergillosis is uncommon and occurs primarily in immunocompromised